In:
Journal of Medical Virology, Wiley, Vol. 93, No. 10 ( 2021-10), p. 5825-5832
Abstract:
The coronavirus disease 2019 (COVID‐19) pandemic has focused attention on the need to develop effective therapeutics against the causative pathogen, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), and also against other pathogenic coronaviruses. In this study, we report on a kind of bisbenzylisoquinoline alkaloid, neferine, as a pan‐coronavirus entry inhibitor. Neferine effectively protected HEK293/hACE2 and HuH7 cell lines from infection by different coronaviruses pseudovirus particles (SARS‐CoV‐2, SARS‐CoV‐2 [D614G, N501Y/D614G, 501Y.V1, 501Y.V2, 501Y.V3 variants], SARS‐CoV, MERS‐CoV) in vitro, with median effect concentration (EC 50 ) of 0.13–0.41 μM. Neferine blocked host calcium channels, thus inhibiting Ca 2+ ‐dependent membrane fusion and suppressing virus entry. This study provides experimental data to support the fact that neferine may be a promising lead for pan‐coronaviruses therapeutic drug development.
Type of Medium:
Online Resource
ISSN:
0146-6615
,
1096-9071
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
752392-0
detail.hit.zdb_id:
1475090-9
Permalink